Literature DB >> 24391386

Canagliflozin (invokana), a novel oral agent for type-2 diabetes.

Sheila Sarnoski-Brocavich, Olga Hilas.   

Abstract

Entities:  

Year:  2013        PMID： 24391386      PMCID： PMC3875253     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


× No keyword cloud information.
  15 in total

1.  Standards of medical care in diabetes--2013.

Authors: 
Journal:  Diabetes Care       Date:  2013-01       Impact factor: 19.112

2.  Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus.

Authors:  Sumihiro Nomura; Shigeki Sakamaki; Mitsuya Hongu; Eiji Kawanishi; Yuichi Koga; Toshiaki Sakamoto; Yasuo Yamamoto; Kiichiro Ueta; Hirotaka Kimata; Keiko Nakayama; Minoru Tsuda-Tsukimoto
Journal:  J Med Chem       Date:  2010-09-09       Impact factor: 7.446

3.  Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence.

Authors:  James P Boyle; Theodore J Thompson; Edward W Gregg; Lawrence E Barker; David F Williamson
Journal:  Popul Health Metr       Date:  2010-10-22

4.  Clinical potential of sodium-glucose cotransporter 2 inhibitors in the management of type 2 diabetes.

Authors:  Yoojin Kim; Ambika R Babu
Journal:  Diabetes Metab Syndr Obes       Date:  2012-08-31       Impact factor: 3.168

5.  Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise.

Authors:  K Stenlöf; W T Cefalu; K-A Kim; M Alba; K Usiskin; C Tong; W Canovatchel; G Meininger
Journal:  Diabetes Obes Metab       Date:  2013-01-24       Impact factor: 6.577

6.  Relationship between obesity and diabetes in a US adult population: findings from the National Health and Nutrition Examination Survey, 1999-2006.

Authors:  Ninh T Nguyen; Xuan-Mai T Nguyen; John Lane; Ping Wang
Journal:  Obes Surg       Date:  2011-03       Impact factor: 4.129

Review 7.  Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Authors:  Silvio E Inzucchi; Richard M Bergenstal; John B Buse; Michaela Diamant; Ele Ferrannini; Michael Nauck; Anne L Peters; Apostolos Tsapas; Richard Wender; David R Matthews
Journal:  Diabetes Care       Date:  2012-04-19       Impact factor: 19.112

8.  The prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes, 1988-2010.

Authors:  Sarah Stark Casagrande; Judith E Fradkin; Sharon H Saydah; Keith F Rust; Catherine C Cowie
Journal:  Diabetes Care       Date:  2013-02-15       Impact factor: 19.112

9.  Economic costs of diabetes in the U.S. in 2012.

Authors: 
Journal:  Diabetes Care       Date:  2013-03-06       Impact factor: 19.112

10.  Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial.

Authors:  Guntram Schernthaner; Jorge L Gross; Julio Rosenstock; Michael Guarisco; Min Fu; Jacqueline Yee; Masato Kawaguchi; William Canovatchel; Gary Meininger
Journal:  Diabetes Care       Date:  2013-04-05       Impact factor: 19.112
View more
  5 in total

1.  Blockade of sodium-glucose cotransporter 2 suppresses high glucose-induced angiotensinogen augmentation in renal proximal tubular cells.

Authors:  Ryousuke Satou; Michael W Cypress; T Cooper Woods; Akemi Katsurada; Courtney M Dugas; Vivian A Fonseca; L Gabriel Navar
Journal:  Am J Physiol Renal Physiol       Date:  2019-11-04

Review 2.  Cardiovascular Drug Interactions With Nirmatrelvir/Ritonavir in Patients With COVID-19: JACC Review Topic of the Week.

Authors:  Sonu Abraham; Anju Nohria; Tomas G Neilan; Aarti Asnani; Anu Mariam Saji; Jui Shah; Tara Lech; Jason Grossman; George M Abraham; Daniel P McQuillen; David T Martin; Paul E Sax; Sourbha S Dani; Sarju Ganatra
Journal:  J Am Coll Cardiol       Date:  2022-10-06       Impact factor: 27.203

Review 3.  Update on the treatment of type 2 diabetes mellitus.

Authors:  Juan José Marín-Peñalver; Iciar Martín-Timón; Cristina Sevillano-Collantes; Francisco Javier Del Cañizo-Gómez
Journal:  World J Diabetes       Date:  2016-09-15

4.  Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors: A Review of Their Basic and Clinical Pharmacology.

Authors:  Sanjay Kalra
Journal:  Diabetes Ther       Date:  2014-11-26       Impact factor: 2.945

Review 5.  The treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapies.

Authors:  Melanie Davies; Sudesna Chatterjee; Kamlesh Khunti
Journal:  Clin Pharmacol       Date:  2016-06-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.